



JPW

Docket No. 75723-ZB/JPW/GJG/CS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: David Baltimore et al.  
Serial No.: 10/037,415 Examiner: C. Hibbert  
Filed : January 4, 2002 Group Art Unit: 1636  
For : NUCLEAR FACTORS ASSOCIATED WITH TRANSCRIPTIONAL  
REGULATION

30 Rockefeller Plaza  
20th Floor  
New York, New York 10112  
February 23, 2008

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants direct the Examiner's attention to the following disclosures, which are also listed on the attached substitute Form PTO-1449 (**Exhibit A**).

The subject application is a continuation under 35 U.S.C. § 120 of U.S. Application No. 08/464,364, filed June 5, 1995, now U.S. Patent No. 6,410,516, issued June 25, 2002, now undergoing reexamination under Control Nos. 90/007,503 and 90/007,828 which have been previously disclosed and brought to the Examiner's attention in the subject application.

Applicants note that item 1 listed herein is part of the merged *Ex Parte* Reexamination Control Nos. 90/007,503 and 90/007,828. Items 2-3 listed herein are part of a concurrent litigation captioned *Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.* The merged reexamination and

02/26/2009 RECD001 00000037 10037415

180.00 OP

01 FC:1806

Applicants : David Baltimore et al.  
Serial No. : 10/037,415  
Filed : January 4, 2002  
Page 2 of 4 of Supplemental Information Disclosure Statement

the concurrent litigation proceedings involve U.S. Patent No. 6,410,516, which issued from a parent of the subject application.

All disclosures are readily available to the Examiner and to the public from the file history of U.S. Patent No. 6,410,516 and its merged reexamination proceeding (*Ex Parte* Reexamination Control Nos. 90/007,503, filed April 4, 2005, and 90/007,828, filed December 2, 2005). Accordingly, copies of items 1-3 are not enclosed.

The Examiner is respectfully requested to make the items of record in the subject application by initialing and dating the attached substitute Form PTO-1449, and returning a copy of the initialed and dated form to Applicants' undersigned attorneys.

1. Advisory Action issued February 14, 2009 in Merged Reexamination Control Nos. 90/007,503 and 90/007,828;
2. Brief of Plaintiffs/Counterclaim Defendants-Appellees Amgen Inc., et al., filed January 28, 2009 in the concurrent litigation captioned *Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.*, U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023; and
3. Reply Brief for Appellants, ARIAD Pharmaceuticals, Inc., et al., filed February 17, 2009 in the concurrent litigation captioned *Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.*, U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023.

Item 1 was issued February 14, 2009 in connection with merged *Ex Parte* Reexamination Control Nos. 90/007,503 and 90/007,828.

Applicants : David Baltimore et al.  
Serial No. : 10/037,415  
Filed : January 4, 2002  
Page 3 of 4 of Supplemental Information Disclosure Statement

Items 2-3 was previously disclosed as Exhibits 1-2 in SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT, filed February 23, 2009, in connection with merged *Ex Parte* Reexamination Control Nos. 90/007,503 and 90/007,828.


This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c)(2), before the mailing of a Final Office Action. Accordingly, Applicants enclose a check in the amount of ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) for filing this Supplemental Information Disclosure Statement.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Applicants: David Baltimore et al.  
Serial No.: 10/037,415  
Filed: January 4, 2002  
Page 4 of 4 of Supplemental Information Disclosure Statement

No fee, other than the enclosed \$180.00 fee for filing a Supplemental Information Disclosure Statement, is deemed necessary in connection with filing this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the additional amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White  
Registration No. 28,678  
Gary J. Gershik  
Registration No. 39,992  
Attorneys for Applicants  
Cooper & Dunham LLP  
30 Rockefeller Plaza  
20th Floor  
New York, New York 10112  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

 2/23/02  
John P. White  
Reg. No. 28,678  
Gary J. Gershik  
Reg. No. 39,992

Date

# **EXHIBIT A**

## **of Supplemental Information Disclosure Statement**

Applicants: David Baltimore, et al.

Serial No.: 10/037,415

Filed: January 4, 2002

Group Art Unit: 1636

Examiner: C. Hibbert